Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2013-10-07 | Mr. Nordhoff's experience as a director and executive officer of pharmaceutical and biotech companies provides our Board with valuable operational expertise and leadership skills. |
| Filing Date | Source Excerpt |
|---|---|
| 2011-04-22 | Henry L. Nordhoff(3) Member of the Audit Committee. Total compensation paid to non-employee directors was $96,735. |
| 2012-04-06 | Henry L. Nordhoff has been one of our directors since March 2005. ... (3) Member of the Audit Committee. ... Director Compensation Table: Henry L. Nordhoff Fees Earned or Paid in Cash $50,500, Option Awards $26,900, Restricted Stock Awards $0, Total $77,400. |
| 2013-04-12 | Henry L. Nordhoff has been one of our directors since March 2005. ... Our Audit Committee consists of Mr. Consiglio (chair), Mr. MacCallum and Mr. Nordhoff ... Our Compensation Committee consists of Mr. Kresa (chair), Mr. Nordhoff, and Dr. Friedman ... The following table sets forth information concerning director compensation received for the fiscal year ended December 31, 2012 by our non-employee directors: ... Henry L. Nordhoff ... Total($) 65,651 |
| 2014-04-11 | Henry L. Nordhoff has been one of our directors since March 2005. ... Our Compensation Committee consists of Mr. Kresa (chair), Mr. Nordhoff, and Dr. Friedman, each of whom is an independent member of our Board of Directors ... Our Audit Committee consists of Mr. Consiglio (chair), Mr. MacCallum and Mr. Nordhoff, each of whom is an independent member of our Board of Directors ... The following table sets forth information concerning director compensation received for the fiscal year ended December 31, 2013 by our non-employee directors. ... Henry L. Nordhoff ... Total($) 163,908 |
| 2015-04-10 | Our Compensation Committee consists of Mr. Kresa (chair), Mr. Nordhoff, and Dr. Friedman, each of whom is an independent member of our Board of Directors. |
| 2016-04-21 | Henry L. Nordhoff has been one of our directors since March 2005. He has served as a director of BioTime, Inc. since June 2013 and as a director of Asterias Biotherapeutics, Inc. since October 2013. Mr. Nordhoff retired as Chairman of the Board of Gen-Probe Incorporated, a clinical diagnostic and blood screening company, at the end of 2011, after serving as its Chairman since September 2002. He also served as Chief Executive Officer and President of Gen-Probe from July 1994 until May 2009. Prior to joining Gen-Probe, he was President and Chief Executive Officer of TargeTech, Inc., a gene therapy company that was merged into Immune Response Corporation. Prior to that, Mr. Nordhoff was at Pfizer, Inc. in senior positions in Brussels, Seoul, Tokyo and New York. He received a B.A. in international relations and political economy from Johns Hopkins University and an M.B.A. from Columbia University. The Board believes that Mr. Nordhoff’s business experience, including his experience as a director and executive officer at pharmaceutical and biotech companies, combined with his business acumen and judgment provide our Board with valuable operational expertise and leadership and qualifies him to serve on our Board of Directors. |
| 2017-02-13 | Named Executive Officers and Directors: Henry L. Nordhoff(11) - Includes 176,333 shares which Mr. Nordhoff has the right to acquire within 60 days of February 1, 2017 pursuant to the exercise of outstanding options. |
| 2017-04-07 | Henry L. Nordhoff has been one of our directors since March 2005. He has served as a director of BioTime, Inc. since June 2013 and as a director of Asterias Biotherapeutics, Inc. since October 2013. Mr. Nordhoff retired as Chairman of the Board of Gen-Probe Incorporated, a clinical diagnostic and blood screening company, at the end of 2011, after serving as its Chairman since September 2002. He also served as Chief Executive Officer and President of Gen-Probe from July 1994 until May 2009. Prior to joining Gen-Probe, he was President and Chief Executive Officer of TargeTech, Inc., a gene therapy company that was merged into Immune Response Corporation. Prior to that, Mr. Nordhoff was at Pfizer, Inc. in senior positions in Brussels, Seoul, Tokyo and New York. He received a B.A. in international relations and political economy from Johns Hopkins University and an M.B.A. from Columbia University. The Board believes that Mr. Nordhoff’s business experience, including his experience as a director and executive officer at pharmaceutical and biotech companies, combined with his business acumen and judgment provide our Board with valuable operational expertise and leadership and qualifies him to serve on our Board of Directors. |
| 2017-11-17 | Includes 2,327 options and 567 restricted stock units which Mr. Nordhoff has the right to acquire within 60 days of October 30, 2017 pursuant to the exercise of outstanding options and vesting of restricted stock units. |
| 2018-03-29 | Henry L. Nordhoff has been one of our directors since March 2005. He has served as a director of BioTime, Inc. since June 2013 and as a director of Asterias Biotherapeutics, Inc. since October 2013. Mr. Nordhoff retired as Chairman of the Board of Gen-Probe Incorporated, a clinical diagnostic and blood screening company, at the end of 2011, after serving as its Chairman since September 2002. He also served as Chief Executive Officer and President of Gen-Probe from July 1994 until May 2009. Prior to joining Gen-Probe, he was President and Chief Executive Officer of TargeTech, Inc., a gene therapy company that was merged into Immune Response Corporation. Prior to that, Mr. Nordhoff was at Pfizer, Inc. in senior positions in Brussels, Seoul, Tokyo and New York. He received a B.A. in international relations and political economy from Johns Hopkins University and an M.B.A. from Columbia University. The Board believes that Mr. Nordhoff's business experience, including his experience as a director and executive officer at pharmaceutical and biotech companies, combined with his business acumen and judgment provide our Board with valuable operational expertise and leadership and qualifies him to serve on our Board of Directors. Director Compensation Table Henry L. Nordhoff FeesEarned or Paid in Cash($) 60,000 OptionAwards($) 33,000 Total($) 93,000 |
| 2019-03-28 | Our Audit Committee consists of Mr. Consiglio (chair), Ms. Mundkur, and Mr. Nordhoff, each of whom is an independent member of our Board of Directors ... Mr. Nordhoff also serves as Chairman of Chugai Pharma USA, a position he has held since January 2013. |
Data sourced from SEC filings. Last updated: 2026-02-03